Cuba working on coronavirus vaccine
Reiterated the director of Science and Innovation of BioCubaFarma, Dr. Rolando Pérez Rodríguez, at the Mesa Redonda television program, and explained the development of products to deal with different pathologies, some registered and others in the research phase.
Dr. Rolando Pérez Rodríguez, director of Science and Innovation of BioCubaFarma, spoke at the Mesa Redonda television program this Friday about the role of the biopharmaceutical industry in the field of science and innovation against the coronavirus.
He said that the laboratories of the Center for Genetic Engineering and Biotechnology (CIGB) were working on a vaccine to induce specific protective immunity. “This is a future project that will allow, in a long-term control of the disease, if there is a re-emergence, having a specific vaccine.”
He said that there is also a vaccine candidate produced by the Carlos J. Finlay Institute based on components of the Cuban vaccine against meningitis, which activates the innate immune system and gives some capacity to react against the virus.
He assured that today there are 41 vaccine projects around the world, but that none has shown effective use, and only five have started the first studies in patients. “Cuban scientists are in that same race,” he said.
He also spoke about the development of technologies that have allowed access to a set of products for different pathologies, some registered and others under investigation.